Science & Technology
Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44CA309843-01
Award Ceiling
$770K
Award Floor
$770K
Close Date
Aug 31, 2028
900 days leftTotal Funding
$770K
Expected Awards
1
Posted Date
Sep 9, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44CA309843-01
Description
SBIR Phase Phase II award: "Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer" awarded to MAIA Biotechnology, Inc. in Chicago, Illinois. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $770,168. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.